Success in IPF trials could validate therapies for broader aging-related conditions
During the first 24 weeks, you may experience: Nausea (the most frequently reported side effect, affecting 20-40% of patients initially, varying by product and dose according to SmPC data) [20] [17] Reduced appetite or early satiety Occasional vomiting Mild abdominal discomfort or bloating Changes in bowel habits, including constipation or diarrhoea These effects typically diminish as your body adjusts to the medication, usually within 48 weeks
A 2022 systematic review in Growth Hormone & IGF Research identified 47 clinical trials involving Tesamorelin versus 23 for Sermorelin reflecting the significantly higher clinical investment in Tesamorelins metabolic applications
These include: Nausea (the most common complaint, particularly during dose escalation) Vomiting Diarrhoea Constipation Decreased appetite These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or following a dose increase
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE- /- and LDLr- /- Mice by a Mechanism That Includes Inflammatory Pathways
Evaluating the Safety of Compounded Semaglutide: Insights from Rock Ridge Pharmacy Regulation and Quality Control: Compounded semaglutide isn't regulated by the FDA like commercial drugs